|1.||Acquired Immunodeficiency Syndrome (AIDS)
|4.||Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia)
|1.||Zhu, Xing-Quan: 23 articles (01/2016 - 07/2009)|
|2.||Hunter, Christopher A: 18 articles (11/2015 - 03/2002)|
|3.||Petersen, Eskild: 16 articles (04/2015 - 06/2003)|
|4.||Flegr, Jaroslav: 15 articles (01/2015 - 07/2003)|
|5.||Dubey, J P: 15 articles (02/2013 - 06/2000)|
|6.||Cong, Hua: 14 articles (11/2015 - 07/2007)|
|7.||He, Shenyi: 13 articles (11/2015 - 07/2007)|
|8.||Pelloux, Hervé: 13 articles (05/2015 - 05/2002)|
|9.||Zhou, Huaiyu: 12 articles (11/2015 - 07/2007)|
|10.||Kur, Józef: 12 articles (10/2015 - 01/2007)|
|1.||Pyrimethamine (Daraprim)FDA Link
01/01/2012 - "In conclusion, toxoplasmosis in heart allographs was more frequent among seronegative heart recipients, and oral pyrimethamine was highly effective for the prevention of T. "
02/01/2014 - "We propose an innovative product based on the nanoencapsulation of pyrimethamine (PYR), aiming an improvement of drug efficacy for the treatment of toxoplasmosis. "
11/01/1953 - "The chemotherapeutic efficacy of 2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine (daraprim) in experimental toxoplasmosis."
06/01/1998 - "Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. "
11/01/2014 - "Two inhibitors exhibited lower effective concentrations than the currently used toxoplasmosis drug pyrimethamine. "
04/01/2001 - "Numerous studies have supported the importance of immunity to SAG1, the most predominant antigen of Toxoplasma tachyzoite, in protection against Toxoplasma gondii infection. "
05/01/2015 - "This is associated with high protection against toxoplasmosis regarding survival and parasite burden, correlated with an increased delivery of antigens by DGNP in airway mucosa cells. "
01/17/2011 - "Additionally, we demonstrate that the ideal composition of vaccine antigens can be equally effective in mice with different genetic backgrounds and variable levels of innate resistance to toxoplasmosis, resulting in strong protection against T. "
10/01/1994 - "The detection of circulating antigens in serum is directly related to the presence of toxoplasmosis in the acute phase in the three models studied and, therefore, may prove very useful in the rapid diagnosis of this disease."
09/01/2013 - "gondii may be an alternative source of antigens which are very useful for the serodiagnosis of toxoplasmosis. "
|3.||Sulfadiazine (Sulphadiazine)FDA Link
01/01/2012 - "Sulphadiazine-induced renal stones in a 63-year-old HIV-infected man treated for toxoplasmosis."
04/01/2009 - "Sulfadiazine-related stones are uncommonly reported, but they could be increasingly encountered owing to the use of sulfadiazine for human immunodeficiency virus-related toxoplasmosis. "
02/01/2004 - "These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis."
09/01/2003 - "Although most cases are due to extrinsic compression, renal tract obstruction can also be due to intraluminal precipitation of sulfadiazine prescribed for maternofoetal toxoplasmosis. "
07/01/2000 - "Sulfadiazine acute nephrotoxicity is reviving specially because of its use in toxoplasmosis in HIV-positive patients. "
|4.||DNA (Deoxyribonucleic Acid)IBA
11/30/2015 - "These results suggested that TgESA10 DNA vaccine could trigger strong humoral and cellular responses and induce partial protection against acute toxoplasmosis. "
04/01/2015 - "These results suggested that TgGST DNA vaccine could trigger strong humoral and cellular responses and induce partial protection against acute toxoplasmosis. "
05/15/2004 - "The simplified PCR protocols, including partial DNA extraction and direct assay of lung tissue, were effective for the diagnosis of toxoplasmosis."
01/01/2014 - "Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondii rhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model."
07/01/2013 - "In this study, we evaluated the immune responses and protection against toxoplasmosis by immunizing ICR mice with a multiantigenic DNA vaccine. "
|5.||Clindamycin (Cleocin)FDA LinkGeneric
06/01/2009 - "To present a case of toxoplasmosis with an atypical presentation and treated successfully with intravitreal clindamycin. "
04/01/1991 - "Further studies should be conducted to establish the efficacy of clindamycin for the treatment of toxoplasmosis in humans."
02/01/1999 - "To determine the contribution to the efficacy of clindamycin in acute murine toxoplasmosis of treatment protocol variables, groups of Swiss Webster mice inoculated intraperitoneally with 10(2) RH strain Toxoplasma gondii tachyzoites were treated with peroral clindamycin at 25, 50 and 400 mg/kgBM per day for 1, 2 and 3 weeks. "
02/01/1999 - "Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis."
06/01/1996 - "The results of the study suggest that clindamycin, when administered at this specific time interval following inoculation, does not ameliorate ocular lesions and has a detrimental effect on the clinical course of acute, experimental toxoplasmosis in cats. "
|6.||Atovaquone (Mepron)FDA Link
02/01/2011 - "SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers."
08/01/2008 - "This paper describes the use of atovaquone for effective treatment of toxoplasmosis in 4 Bennett's wallabies (Macropus rufogriseus), along with the serology, isolation of Toxoplasma gondii, and genotyping of 3 T. "
09/12/1992 - "Atovaquone is a well-tolerated drug that appears to be an effective alternative for patients with toxoplasmosis who are intolerant of standard therapies."
09/01/2012 - "We hypothesized atovaquone to be safe and effective against feto-maternal Toxoplasmosis. "
10/01/2014 - "Atovaquone is an effective antiprotozoal agent against toxoplasmosis with minor side effects. "
|7.||Azithromycin (Zithromax)FDA LinkGeneric
03/01/2005 - "Azithromycin alone was found to be effective in the prophylaxis of murine toxoplasmosis. "
09/01/2003 - "Azithromycin was found to be effective at 200 mg/kg/day and above in the prophylaxis, at 250 mg/kg/day and above in the treatment of toxoplasmosis. "
09/01/2003 - "A murine toxoplasmosis model with Balb/C mice was used to investigate the therapeutic and prophylactic efficacy of azithromycin in a native strain of Toxoplasma gondii. "
09/01/2003 - "Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondii strain from Turkey."
07/01/1994 - "The efficacy of prolonged administration of azithromycin was evaluated in a murine model of lethal chronic toxoplasmosis. "
|8.||Immunoglobulin G (IgG)IBA
01/01/2013 - "In current study, modification and importance of improved Toxoplasma Avidity IgG testing has been evlauated for differentiating Toxoplasma gondii infection in early stage of pregnancy. "
10/01/2005 - "Women with positive results were then retested with the Toxo-IgG avidity assay for recent toxoplasmosis. "
08/01/1997 - "Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity."
03/01/1993 - "Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG."
05/01/2014 - "The aim of the study was to evaluate the performance of the ImmunoComb® Toxo IgG and ImmunoComb® Toxo IgMassays (rapid diagnostic test) in the laboratory diagnosis of toxoplasmosis in pregnant women in Cotonou. "
|9.||Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)FDA LinkGeneric
08/01/2015 - "Several observational studies have demonstrated the efficacy of trimethoprim-sulfamethoxazole (TMP/SMX) in decreasing the incidence of toxoplasmosis following HCT. "
12/01/1999 - "To evaluate the influence of the dose of co-trimoxazole prophylaxis on the risk of toxoplasmosis in human immunodeficiency virus (HIV)-infected patients, we performed a nested case-control study of 32 patients with toxoplasmosis (case patients) and 64 patients without toxoplasmosis (control patients) who were matched by CD4 cell count and Toxoplasma gondii serostatus; these patients were from a cohort of 521 HIV-infected patients who underwent a diagnostic neuroimaging study between March 1993 and January 1997. "
04/01/2014 - "The incidence of recurrent toxoplasmosis retinochoroiditis within 12 months was 0 of 46 (0%) and 6 of 47 (12.80%) in the trimethoprim-sulfamethoxazole and placebo groups, respectively (P = .026). "
04/01/2014 - "The initially active toxoplasmosis lesions were successfully treated in all cases using trimethoprim-sulfamethoxazole (800 mg/160 mg) twice daily for 45 days. "
01/01/2014 - "The monitoring of these patients was defined by a history of positive serology for toxoplasmosis in the donor or recipient and because their hematologic condition did not allow the use of trimethoprim-sulfamethoxazole for prophylaxis. "
|10.||Proteins (Proteins, Gene)IBA
12/15/2014 - "However, the most effective for diagnosis of toxoplasmosis in sheep, based on the highest absorbance values, was the mixture M4 containing three proteins. "
01/17/2011 - "The strongest protection against chronic toxoplasmosis was induced in both C3H/HeJ and C57BL/6 mice by the mixture of rhoptry proteins rROP2 and rROP4 combined with tachyzoite major protein rSAG1. "
09/01/2009 - "Toxoplasma gondii: the immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis."
07/01/2007 - "A combination of antigenic regions of microneme proteins have been previously reported as being protective against chronic toxoplasmosis. "
01/01/2015 - "In the present study, we used different recombinant microneme proteins (TgMIC1, TgMIC4, or TgMIC6) or combinations of these proteins (TgMIC1-4 and TgMIC1-4-6) to evaluate the immune response and protection against experimental toxoplasmosis in C57BL/6 mice. "
12/01/2015 - "Authors hereby report an unusual case of a 57-year-old male who developed retinochoroidal toxoplasmosis after 15 years of renal transplant, the diagnoses of which were challenging as the patient was also a known case of cerebral post-transplant lymphoproliferative disease (PTLD) of Hodgkin's type, which misled the ophthalmologists towards a clinical diagnosis of ocular PTLD. "
12/01/2015 - "Retinochoroidal toxoplasmosis in a patient with cerebral post-transplant lymphoproliferative disease of Hodgkin's type: a diagnostic challenge."
08/01/2015 - "Toxoplasmosis in haematopoietic cell transplant (HCT) recipients is associated with high morbidity and mortality rates. "
03/01/2013 - "Toxoplasmosis is a potential complication in autologous as well as allogeneic transplants, and should be considered in any post-HCT patient with neurological dysfunction. "
02/01/2013 - "Patients with negative pre-transplant Toxoplasma serology should therefore be considered at risk for toxoplasmosis after allogeneic HSCT. "
|2.||Drug Therapy (Chemotherapy)
11/01/1992 - "A mouse model was developed and used to study the effects that depletion of CD4+ T cells and/or inhibition of the protective activity of IFN-gamma have on the effectiveness of the drug therapy for toxoplasmosis. "
01/01/1953 - "[Studies on chemotherapy of experimental toxoplasmosis]."
03/01/2012 - "This review covers different approaches to toxoplasmosis chemotherapy focused on the metabolic differences between the host and the parasite. "
10/01/2009 - "Immunocompromised patients are at risk of developing toxoplasmosis, and although chemotherapy is available, standard treatments are often complicated by severe side effects. "
01/01/2005 - "The patient showed clinical improvement following specific chemotherapy for toxoplasmosis. "
|3.||Transplantation (Transplant Recipients)
04/15/2008 - "Toxoplasmosis has been reported to occur in noncardiac transplant recipients; however, no large studies examining the frequency of such events or the need for serologic screening exist. "
05/01/1986 - "Systematic clinical and serological studies to evaluate the frequency of toxoplasmosis in bone marrow transplant recipients were performed in 80 consecutive patients. "
01/01/2013 - "The literature reports toxoplasmosis as an uncommon but dangerous source of morbidity and mortality after transplantation. "
12/01/2012 - "In conclusion, for the determination of patients at risk of toxoplasmosis, clinicians should consider buffy coat PCR in combination with serology before transplantation. "
12/01/2012 - "After transplantation, these patients experienced toxoplasmosis. "
11/01/1996 - "The patient's symptoms resolved after treatment of toxoplasmosis. "
10/01/1994 - "We hypothesize that demonstration of persistent areas of contrast enhancement after treatment for initial toxoplasmosis may be a valuable sign for identifying patients at risk for recurrence."
05/01/1993 - "Cardiac toxoplasmosis was present in one of these cases, and signal intensity returned to baseline after treatment.(ABSTRACT TRUNCATED AT 250 WORDS)"
01/01/1973 - "[Toxoplasmosis and generalized mycosis after treatment of chronic myelosis (author's transl)]."
09/01/2011 - "Hidden in plain view: emergence of progressive multifocal leukoencephalopathy after treatment of CNS toxoplasmosis."
|5.||Highly Active Antiretroviral Therapy (HAART)
04/01/2012 - "HIV-associated toxoplasmosis hospitalizations dropped markedly after 1995 when highly active antiretroviral therapy was introduced; however, hospitalizations decreased relatively little after 2000, suggesting late diagnosis of some HIV-infected persons or antiretroviral therapy failure. "
04/01/2010 - "Pulmonary toxoplasmosis is rare, particularly in the era of highly active antiretroviral therapy (HAART). "
01/01/2002 - "Highly active antiretroviral therapy has improved the prognosis of several focal CNS processes, most notably toxoplasmosis, PML, and CMV encephalitis."
01/01/2013 - "These findings led us to conclude that the study population is at high risk of clinical toxoplasmosis, because of both reactivation of infection in the seropositive patients who do not make a regular use of HAART, and primo-infection in seronegative patients worsened by an unawareness of the modes of infection reported in this study."
10/01/2005 - "One year after the diagnosis, all available patients were on HAART and toxoplasmosis prophylaxis, and only 2 patients had relapse of cerebral toxoplasmosis. "